Quotient Sciences

Quotient Sciences is a drug development and manufacturing accelerator that has been transforming the pharmaceutical industry since 1990. Founded as a spin-out from the University of Nottingham, the company has grown from its UK origins into a global organization with facilities spanning both the United States and United Kingdom. As a CRDMO (Contract Research, Development, and Manufacturing Organization), Quotient Sciences provides comprehensive, integrated services that support customers across the entire drug development pathway.

The company's unique value proposition lies in its Translational Pharmaceutics® platform, a proprietary approach that integrates clinical activities with real-time cGMP drug product manufacturing. This innovative model eliminates traditional silos in drug development, enabling faster decision-making and significantly accelerating timelines from candidate selection to commercial supply. Quotient Sciences serves a diverse client base ranging from emerging biotech companies to Fortune 100 pharmaceutical corporations, offering formulation development, clinical pharmacology trials, Phase I/IIa clinical studies, and commercial manufacturing services.

With over 35 years of experience and more than 1,000 experts across its global operations, Quotient Sciences has established itself as a trusted partner in bringing molecules to cures, fast. The company's commitment to scientific integrity, agility, and collaborative culture has earned it multiple industry awards, including CRO Leadership Awards and CDMO Leadership Awards, recognizing excellence in Phase I clinical studies and innovative solutions in drug development.